<DOC>
	<DOC>NCT00615693</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<criteria>Male and female patients with noninfectious intermediate or posterior uveitis or panuveitis in at least one eye, age 18 to 70 years of age inclusive, who are otherwise in good health Macular edema with average central retinal thickness ≥ 250 µm A vitreous haze score ≥ 1, but ≤ 3 (based on the National Eye Institute grading system) Best Corrected Visual Acuity no worse than 20/400 and no better than 20/40 Daily prednisone dose &lt; 1 mg/kg Patients with choroidal neovascularization. Patients with the following forms of uveitis: 1. Serpiginous choroidopathy 2. Acute multifocal placoid pigment epitheliopathy 3. White dot retinochoroidopathies (e.g., multiple evanescent white dot syndrome (MEWDS) or multifocal choroiditis) Macular edema associated with other ocular disease (e.g., diabetic retinopathy) Patients who had a prior vitrectomy Any eye condition that may affect the evaluation of visual acuity and retinal thickness Concurrent use of certain immunosuppressive agents (specific washout periods for different agents are defined in the protocol) Use of systemic medications known to be toxic to the lens, retina, or optic nerve (e.g. deferoxamine, chloroquine, and ethambutol) currently or in the past 6 months Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Macular Edema</keyword>
</DOC>